Ịṅụ Oncogene
Oncogene riri ahụ [1] bụ usoro nke ọrịa kansa nwere mkpụrụ ndụ ihe nketa, epijenetic, ma ọ bụ kromozomal irregularities na-adabere na otu ma ọ bụ ọtụtụ mkpụrụ ndụ ihe mere eme maka nlekọta na ịdị ndụ. [2]'N' hi ya, mkpụrụ ndụ kansa na-adabere na mgbaàmà na-aga n'ihu site na oncogenes ndị a maka ndụ ha. [3] Ọ bụ dọkịta Amerịka a bụ I. Bernard Weinstein chepụtara okwu ahụ n'afọ 2002.
Ọmụmaatụ
[dezie | dezie ebe o si]Ihe atụ kachasị mma nke ọrịa kansa nke na [4]-egosipụta ihe riri ahụ na oncogene bụ ọrịa lukemia myelogenous (CML), nke oncogene na-agbanwe agbanwe a maara dị ka Philadelphia kromozom na-akpali. [5] na-akpọ CML "ọrịa postter-nwatakịrị maka ịṅụ ọgwụ ọjọọ". [4] Ịmaatụ ndị ọzọ gụnyere gastrointestinal stromal tumor, nke nwere ike ịbụ ihe riri ahụ na mkpụrụ ndụ ihe nketa KIT; melanoma, nke nwere ikike ịbụ ihe riri ya ahụ na mkpụrụedemede BRAF; na carcinoma akpa ume na-abụghị obere mkpụrụ ndụ, nke nwere ohere ịbụ ihe riri mmadụ ahụ na mkpụrụọn ihe nketa EGFR.
E nwere ike ịgwọ ọgwụ Oncogene site n'iji ọgwụgwọ enzyme inhibitor. Ih[4] atụ nke ihe mgbochi ndị e ji gbochie oncogenes ma mebie oncogene riri ahụ gụnyere imatinib, nilotinib, dasatinib, na ponatinib, n'etiti ndị ọzọ. [2][4] bụ ezie na ọgwụgwọ mbụ nwere ike inwe nsonaazụ dị mma maka ịchịkwa ọrịa kansa, ọgwụgwọ na-adịghị ala ala na-akpatakarị iguzogide ọgwụ na ịlaghachi. Mgbochi Oncogene na-akpatakarị ndụ na-enweghị ọganihu nke ọnwa ole na ole, nke pụtara na ọtụtụ ọgwụgwọ ọrịa kansa na-adabere na ọgwụgwọ kemịkal. Ihe dị ịrịba ama bụ ihe ịga nke ọma nke ọgwụgwọ inhibitorna ịgwọ CML. Usoro ọgwụgwọ inhibitor enweela ihe ịga nke ọma [5] ọrịa a, a ka na-amaghị oge ndụ na-enweghị ọganiihu, ebe ọ bụ na enwetabeghị ya n'ihe karịrị afọ iri nke nsochi azụ.
Nghọta ndị ọzọ na-adịbeghị anya banyere mgbochi mgbochi bụ na mgbochi nke otu mkpụrụ ndụ ihe nketa nwere ike ime ka ụzọ mgbaàmà laghachi. Mgbe[5] e nwere ike ịzọpụta usoro ndị na-agbadata na-egosi ma na-elekọta ọrịa kansa.
- ↑ Joe (2011). "Oncogene Addiction", Encyclopedia of Cancer, 2616–2622. DOI:10.1007/978-3-642-16483-5_4222. ISBN 978-3-642-16482-8.
- ↑ 2.0 2.1 Nagel (2016). "Drugging the addict: Non‐oncogene addiction as a target for cancer therapy". EMBO Reports 17 (11): 1516–1531. DOI:10.15252/embr.201643030. PMID 27702988. Kpọpụta njehie: Invalid
<ref>tag; name "Nagel" defined multiple times with different content - ↑ Tulpule (2020). "Acquired Resistance in Lung Cancer". Annual Review of Cancer Biology 4: 279–297. DOI:10.1146/annurev-cancerbio-030419-033502.
- ↑ 4.0 4.1 4.2 4.3 Pagliarini (2015). "Oncogene addiction: Pathways of therapeutic response, resistance, and road maps toward a cure". EMBO Reports 16 (3): 280–296. DOI:10.15252/embr.201439949. PMID 25680965. Kpọpụta njehie: Invalid
<ref>tag; name "Pagliarini" defined multiple times with different content - ↑ 5.0 5.1 5.2 Amin (2015). "Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells". Biomarkers in Cancer 7s2 (Suppl 2): 25–32. DOI:10.4137/BIC.S29326. PMID 26688666. Kpọpụta njehie: Invalid
<ref>tag; name "Rajan" defined multiple times with different content